STOCK TITAN

[Form 4] Phibro Animal Health Corporation Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Jack Bendheim, who is listed as a director, 10% owner and President and CEO of Phibro Animal Health Corp (PAHC), reported a non‑derivative acquisition on 08/15/2025 of 16,840 restricted stock units (RSUs). Each RSU represents a contingent right to one share of Class A common stock and was reported at a $0 price.

The filing shows 76,320 shares beneficially owned by the reporting person after the transaction. The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to continued employment. The Form 4 was signed by an attorney‑in‑fact on behalf of Mr. Bendheim on 08/19/2025.

Jack Bendheim, indicato come amministratore, azionista al 10% e Presidente e Amministratore Delegato di Phibro Animal Health Corp (PAHC), ha dichiarato un’acquisizione non derivata in data 15/08/2025 di 16.840 restricted stock units (RSU). Ogni RSU corrisponde al diritto condizionale su una azione di classe A e l’operazione è stata riportata con prezzo di $0.

La comunicazione indica che, dopo la transazione, la persona segnalante detiene beneficiariamente 76.320 azioni. Le RSU maturano in quote sostanzialmente uguali in ciascuno dei primi tre anniversari del 1 agosto 2025, subordinatamente al mantenimento dell’impiego. Il Modulo 4 è stato firmato per procura da un legale in data 19/08/2025.

Jack Bendheim, registrado como director, propietario del 10% y Presidente y CEO de Phibro Animal Health Corp (PAHC), informó una adquisición no derivada el 15/08/2025 de 16.840 unidades restringidas de acciones (RSU). Cada RSU representa el derecho contingente a una acción de clase A y se declaró a un precio de $0.

El informe muestra 76.320 acciones en propiedad beneficiaria de la persona informante tras la operación. Las RSU se consolidan en cuotas sustancialmente iguales en cada uno de los primeros tres aniversarios del 1 de agosto de 2025, sujeto a la continuidad del empleo. El Formulario 4 fue firmado por un apoderado en nombre del Sr. Bendheim el 19/08/2025.

잭 벤드하임(Jack Bendheim)은 이사이자 10% 지분 보유자이며 Phibro Animal Health Corp (PAHC)의 사장 겸 CEO로 등재되어 있으며, 2025-08-1516,840개의 제한부 주식 단위(RSU)를 비파생 방식으로 취득했다고 신고했습니다. 각 RSU는 클래스 A 보통주의 1주에 대한 조건부 권리를 나타내며, 거래 가격은 $0로 신고되었습니다.

신고서에는 거래 후 보고인이 실질적으로 보유한 주식 수가 76,320주로 기재되어 있습니다. RSU는 2025년 8월 1일의 첫 번째 기념일을 시작으로 향후 3개 기념일마다 거의 동일한 비율로 베스팅되며, 이는 계속 고용 상태라는 조건이 있습니다. Form 4는 2025-08-19에 벤드하임 씨를 대신해 대리인이 서명했습니다.

Jack Bendheim, inscrit en tant qu'administrateur, propriétaire à 10% et Président‑directeur général de Phibro Animal Health Corp (PAHC), a déclaré une acquisition non dérivée le 15/08/2025 de 16 840 unités d'actions restreintes (RSU). Chaque RSU représente le droit conditionnel sur une action de la classe A et a été déclarée au prix de 0 $.

Le dépôt indique que la personne déclarante détient au total 76 320 actions après la transaction. Les RSU acquièrent des droits par tranches sensiblement égales à chacun des trois premiers anniversaires du 1er août 2025, sous réserve de la poursuite de l'emploi. Le formulaire 4 a été signé par un mandataire au nom de M. Bendheim le 19/08/2025.

Jack Bendheim, der als Director, 10%iger Eigentümer sowie President und CEO von Phibro Animal Health Corp (PAHC) geführt wird, meldete am 15.08.2025 den nicht-derivaten Erwerb von 16.840 Restricted Stock Units (RSUs). Jede RSU gewährt das bedingte Recht auf eine Aktie der Klasse A; der Erwerb wurde mit einem Preis von $0 angegeben.

Die Meldung weist 76.320 wirtschaftlich gehaltene Aktien der meldenden Person nach der Transaktion aus. Die RSUs werden in annähernd gleichen Raten an jedem der ersten drei Jahrestage des 1. August 2025 vesten, vorbehaltlich fortgesetzter Anstellung. Das Formular 4 wurde am 19.08.2025 von einem Bevollmächtigten im Namen von Herrn Bendheim unterschrieben.

Positive
  • Equity alignment: The RSU grant increases the reporting person's stake to 76,320 shares, aligning executive and shareholder interests.
  • Retention focus: Time‑based vesting over three years encourages continued executive service without immediate dilution from exercised options.
Negative
  • None.

Insights

TL;DR: A routine executive equity grant that increases insider alignment without immediate cash cost or market sale.

The 16,840 RSU award is reported as a non‑cash grant and increases the reporting person's beneficial ownership to 76,320 shares, which can signal management alignment with shareholders. Vesting over three years ties value realization to continued service rather than immediate liquidity, limiting near‑term dilution and market impact. There is no exercise price because these are RSUs, not options, and no sale or purchase of open‑market shares is recorded.

TL;DR: Standard executive compensation disclosure; vesting schedule conditions are time‑based and employment‑contingent.

The Form 4 documents a compensatory equity award subject to continued employment, a common corporate governance practice to retain senior executives. Reporting the award under Section 16 satisfies transparency requirements for insider holdings. The filing identifies the reporting person as director, 10% owner and President and CEO, clarifying potential related‑party considerations for governance review.

Jack Bendheim, indicato come amministratore, azionista al 10% e Presidente e Amministratore Delegato di Phibro Animal Health Corp (PAHC), ha dichiarato un’acquisizione non derivata in data 15/08/2025 di 16.840 restricted stock units (RSU). Ogni RSU corrisponde al diritto condizionale su una azione di classe A e l’operazione è stata riportata con prezzo di $0.

La comunicazione indica che, dopo la transazione, la persona segnalante detiene beneficiariamente 76.320 azioni. Le RSU maturano in quote sostanzialmente uguali in ciascuno dei primi tre anniversari del 1 agosto 2025, subordinatamente al mantenimento dell’impiego. Il Modulo 4 è stato firmato per procura da un legale in data 19/08/2025.

Jack Bendheim, registrado como director, propietario del 10% y Presidente y CEO de Phibro Animal Health Corp (PAHC), informó una adquisición no derivada el 15/08/2025 de 16.840 unidades restringidas de acciones (RSU). Cada RSU representa el derecho contingente a una acción de clase A y se declaró a un precio de $0.

El informe muestra 76.320 acciones en propiedad beneficiaria de la persona informante tras la operación. Las RSU se consolidan en cuotas sustancialmente iguales en cada uno de los primeros tres aniversarios del 1 de agosto de 2025, sujeto a la continuidad del empleo. El Formulario 4 fue firmado por un apoderado en nombre del Sr. Bendheim el 19/08/2025.

잭 벤드하임(Jack Bendheim)은 이사이자 10% 지분 보유자이며 Phibro Animal Health Corp (PAHC)의 사장 겸 CEO로 등재되어 있으며, 2025-08-1516,840개의 제한부 주식 단위(RSU)를 비파생 방식으로 취득했다고 신고했습니다. 각 RSU는 클래스 A 보통주의 1주에 대한 조건부 권리를 나타내며, 거래 가격은 $0로 신고되었습니다.

신고서에는 거래 후 보고인이 실질적으로 보유한 주식 수가 76,320주로 기재되어 있습니다. RSU는 2025년 8월 1일의 첫 번째 기념일을 시작으로 향후 3개 기념일마다 거의 동일한 비율로 베스팅되며, 이는 계속 고용 상태라는 조건이 있습니다. Form 4는 2025-08-19에 벤드하임 씨를 대신해 대리인이 서명했습니다.

Jack Bendheim, inscrit en tant qu'administrateur, propriétaire à 10% et Président‑directeur général de Phibro Animal Health Corp (PAHC), a déclaré une acquisition non dérivée le 15/08/2025 de 16 840 unités d'actions restreintes (RSU). Chaque RSU représente le droit conditionnel sur une action de la classe A et a été déclarée au prix de 0 $.

Le dépôt indique que la personne déclarante détient au total 76 320 actions après la transaction. Les RSU acquièrent des droits par tranches sensiblement égales à chacun des trois premiers anniversaires du 1er août 2025, sous réserve de la poursuite de l'emploi. Le formulaire 4 a été signé par un mandataire au nom de M. Bendheim le 19/08/2025.

Jack Bendheim, der als Director, 10%iger Eigentümer sowie President und CEO von Phibro Animal Health Corp (PAHC) geführt wird, meldete am 15.08.2025 den nicht-derivaten Erwerb von 16.840 Restricted Stock Units (RSUs). Jede RSU gewährt das bedingte Recht auf eine Aktie der Klasse A; der Erwerb wurde mit einem Preis von $0 angegeben.

Die Meldung weist 76.320 wirtschaftlich gehaltene Aktien der meldenden Person nach der Transaktion aus. Die RSUs werden in annähernd gleichen Raten an jedem der ersten drei Jahrestage des 1. August 2025 vesten, vorbehaltlich fortgesetzter Anstellung. Das Formular 4 wurde am 19.08.2025 von einem Bevollmächtigten im Namen von Herrn Bendheim unterschrieben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BENDHEIM JACK

(Last) (First) (Middle)
300 FRANK W. BURR BLVD., STE 21

(Street)
TEANECK NJ 07666

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PHIBRO ANIMAL HEALTH CORP [ PAHC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock(1) 08/15/2025 A 16,840(2) A $0 76,320 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock.
2. The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to the Reporting Person's continued employment through the applicable vesting date.
Remarks:
Exhibit List - Exhibit 24.1 Power of Attorney
/s/ Judith Weinstein, as Attorney-in-Fact for Jack Bendheim 08/19/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Jack Bendheim report on Form 4 for PAHC?

He reported acquisition of 16,840 restricted stock units (RSUs) on 08/15/2025, each representing a contingent right to one Class A share.

How many shares does the reporting person own after this transaction?

The filing shows the reporting person beneficially owns 76,320 shares following the reported transaction.

What is the vesting schedule for the RSUs reported for PAHC?

The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to continued employment.

Was there any cash paid for the RSUs in this Form 4?

No cash price is reported; the RSUs are shown with a $0 price in the Form 4 filing.

Who signed the Form 4 on behalf of Jack Bendheim?

The Form 4 was signed by Judith Weinstein, as Attorney‑in‑Fact, on 08/19/2025.
Phibro Animal

NASDAQ:PAHC

PAHC Rankings

PAHC Latest News

PAHC Latest SEC Filings

PAHC Stock Data

1.26B
20.22M
0.59%
104.36%
2.53%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
TEANECK